Dexcom (DXCM) Gross Margin (2010 - 2026)

Dexcom (DXCM) has 17 years of Gross Margin data on file, last reported at 62.95% in Q1 2026.

• Gross Margin for Q1 2026 came in at 62.95%, up 610.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 61.5% (up 207.0% YoY), and the FY2025 annual result was 60.1%, down 36.0% from the prior year.
• Gross Margin was little changed at 62.95% in Q1 2026 per DXCM's latest filing, from 62.93% in the prior quarter.
• Over five years, Gross Margin peaked at 66.4% in Q4 2022 and troughed at 56.85% in Q1 2025.
• A 5-year average of 62.1% and a median of 62.71% in 2023 frame the typical range for Gross Margin.
• The sharpest annual moves came in 2022 and 2026: Gross Margin sank 552 bps in 2022, then jumped 610 bps in 2026.
• A 5-year view of Gross Margin shows it stood at 66.4% in 2022, then declined by 4 bps to 63.47% in 2023, then retreated by 7 bps to 58.9% in 2024, then rose by 7 bps to 62.93% in 2025, then climbed by 0 bps to 62.95% in 2026.
• Business Quant data shows DXCM's Gross Margin at 62.95% in Q1 2026, 62.93% in Q4 2025, and 60.48% in Q3 2025.